Hyperhomocysteinemia in health and disease: Where we are now, and where do we go from here?

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 12, 2012, Pages 2075-2080

  Lippi, Giuseppe ^a   Plebani, Mario ^b,c  

^a ACADEMIC HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Cardiovascular disease; Homocysteine; Hyperhomocysteinemia; Risk factor; Venous thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BETAINE HOMOCYSTEINE METHYLTRANSFERASE; COBALAMIN; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; CYSTEINE; FENOFIBRATE; FOLIC ACID; HOMOCYSTEINE; LIPOPROTEIN A; METHIONINE; METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; PLACEBO; PYRIDOXINE; TRIACYLGLYCEROL;

ALZHEIMER DISEASE; ANTITHROMBIN DEFICIENCY; ARTERY THROMBOSIS; BIRTH WEIGHT; BONE STRENGTH; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CATALYSIS; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEEP VEIN THROMBOSIS; DEPRESSION; FOLLOW UP; FRACTURE; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LOW BIRTH WEIGHT; META ANALYSIS (TOPIC); MULTIINFARCT DEMENTIA; NEURAL TUBE DEFECT; OSTEOLYSIS; PANCREATITIS; PERIODONTAL DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREMATURE FETUS MEMBRANE RUPTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA ARTERY OCCLUSION; RETINA VEIN OCCLUSION; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SMOKING; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VEIN THROMBOSIS; VITAMIN SUPPLEMENTATION;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; PREGNANCY; PREGNANCY COMPLICATIONS; VENOUS THROMBOSIS;

EID: 84872849118     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0372     Document Type: Review

References (39)

1. McCully KS. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr 2007;86:1563S-8S.
2. Malinowska A, Chmurzynska A. Polymorphism of genes encoding homocysteine metabolism-related enzymes and risk for cardiovascular disease. Nutr Res 2009;29:685-95.
3. Haj Mouhamed D, Ezzaher A, Neffati F, Douki W, Najjar MF. Effect of cigarette smoking on plasma homocysteine concentrations. Clin Chem Lab Med 2011;49:479-83.
4. Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost 2008;34:747-61.
5. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 2011;8:502-2.
6. Lippi G, Favaloro EJ, Cervellin G. Hemostatic properties of the lymph: relationships with occlusion and thrombosis. Semin Thromb Hemost 2012;38:213-21.
7. Favaloro EJ, Franchini M, Lippi G. Coagulopathies and thrombosis: usual and unusual causes and associations. Part V. Semin Thromb Hemost 2011;37:859-62.
8. Zoellner H. Dental infection and vascular disease. Semin Thromb Hemost 2011;37:181-92.
9. Pajič T. Factor V Leiden and FII 20210 testing in thromboembolic disorders. Clin Chem Lab Med 2010;48(Suppl 1): S79-87.
10. Bereczky Z, Kovács KB, Muszbek L. Protein C and protein S deficiencies: similarities and differences between two brothers playing in the same game. Clin Chem Lab Med 2010;48(Suppl 1):S53-66.
11. Herrmann W, Obeid R. Homocysteine: a biomarker in neurodegenerative diseases. Clin Chem Lab Med 2011;49:435-41.
12. Nilsson K, Gustafson L, Nornholm M, Hultberg B. Plasma homocysteine, apolipoprotein E status and vascular disease in elderly patients with mental illness. Clin Chem Lab Med 2010;48:129-35.
13. Gomes TS, Lindner U, Tennekoon KH, Karandagoda W, Gortner L, Obeid R. Homocysteine in small-for-gestational age and appropriate-for-gestational age preterm neonates from mothers receiving folic acid supplementation. Clin Chem Lab Med 2010;48:1157-61.
14. Ahmadieh H, Arabi A. Vitamins and bone health: beyond calcium and vitamin D. Nutr Rev 2011;69:584-98.
15. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005;3:292-9.
16. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008;83: 1203-12.
17. Khandanpour N, Loke YK, Meyer FJ, Jennings B, Armon MP. Homocysteine and peripheral arterial disease: systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2009;38:316-22.
18. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc 2002;288:2015-22.
19. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003;136:1136-50.
20. Van Dam F, Van Gool WA. Hyperhomocysteinemia and Alzheimer's disease: A systematic review. Arch Gerontol Geriatr 2009;48:425-30.
21. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 2006;11: 143-9.
22. Almeida OP, McCaul K, Hankey GJ, Norman P, Jamrozik K, Flicker L. Homocysteine and depression in later life. Arch Gen Psychiatry 2008;65:1286-94.
23. Ho RC, Cheung MW, Fu E, Win HH, Zaw MH, Ng A, et al. Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression. Am J Geriatr Psychiatry 2011;19:607-17.
24. Nelen WL, Blom HJ, Steegers EA, den Heijer M, Eskes TK. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril 2000;74:1196-9.
25. Hogeveen M, Blom HJ, den Heijer M. Maternal homocysteine and small-for-gestational-age offspring: systematic review and meta-analysis. Am J Clin Nutr 2012;95:130-6.
26. Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2009;(4):CD006612.
27. Clarke R, Halsey J, Bennett D, Lewington S. Homocysteine and vascular disease: review of published results of the homocysteine-lowering trials. J Inherit Metab Dis 2011;34: 83-91.
28. den Heijer M, Willems HP, Blom HJ, Gerrits WB, Cattaneo M, Eichinger S, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood 2007;109:139-44.
29. Mei W, Rong Y, Jinming L, Yongjun L, Hui Z. Effect of homocysteine interventions on the risk of cardiocerebrovascular events: a meta-analysis of randomised controlled trials. Int J Clin Pract 2010;64:208-15.
30. Sun Y, Lu CJ, Chien KL, Chen ST, Chen RC. Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, doubleblind, placebo-controlled study in Taiwanese patients. Clin Ther 2007;29:2204-14.
31. Kwok T, Lee J, Law CB, Pan PC, Yung CY, Choi KC, et al. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. Clin Nutr 2011;30:297-302.
32. Ueland PM, Vollset SE. Homocysteine and folate in pregnancy. Clin Chem 2004;50:1293-5.
33. Murphy MM, Fernandez-Ballart JD. Homocysteine in pregnancy. Adv Clin Chem 2011;53:105-37.
34. Lippi G, Guidi G. Lipoprotein(a): an emerging cardiovascular risk factor. Crit Rev Clin Lab Sci 2003;40:1-42.
35. Lippi G, Targher G, Franchini M, Guidi GC. Has homocysteine shrunk? Clin Chem Lab Med 2007;45:1419-20.
36. Herrmann M, Whiting MJ, Veillard AS, Ehnholm C, Sullivan DR, Keech AC; for the FIELD study. Investigators plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study. Clin Chem Lab Med 2012;50:2213-9.
37. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
38. Poredos P, Jezovnik MK. Dyslipidemia, statins, and venous thromboembolism. Semin Thromb Hemost 2011;37:897-902.
39. Lippi G, Favaloro EJ, Montagnana M, Franchini M. C-reactive protein and venous thromboembolism: causal or casual association? Clin Chem Lab Med 2010;48:1693-701.